Atsena eye disease gene therapy hits safety goals, closes retinal splits in phase 1/2
Hot on the heels of a $150 million fundraise, gene therapy outfit Atsena Therapeutics has debuted data showing that the company’s eye disease candidate led to no serious treatment-related adverse events and improved the structure and function of the retina.
Hot on the heels of a $150 million fundraise, gene therapy outfit Atsena Therapeutics has debuted data showing that the company’s eye disease candidate led to no serious treatment-related adverse events and improved the structure and function of the retina.
